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Journal of Hepatology 51 (2009) 224–229Comments on the EASL practice guidelines for the management
of chronic hepatitis B: Controversies in interferon-based therapyqTo the Editor:
With great interest we read the new EASL clinical
practice guidelines for the management of chronic hep-
atitis B. First, we would, like to complement the authors
with these concise and well-written guidelines. The man-
uscript provides valuable information and a ﬁrm helping
hand for the many practicing clinicians around the globe
struggling with diﬀerent treatment modalities for
chronic hepatitis B virus (HBV) infection. In particular,
the distinction between sustained oﬀ-treatment response
and treatment maintained response is of great impor-
tance. In addition, the clear recommendation for the
strongest antivirals and the schedule for follow-up of
antiviral therapy are important new concepts in these
guidelines. There are however some concerns we would
like to raise, particularly concerning the recommenda-
tions for interferon (IFN)-treated patients.
The authors provided a clear overview of response
rates after a 1-year course of therapy. It is well known
that HBeAg loss rates increase with prolonged duration
of nucleos(t)ide analogue (NA) therapy and may eventu-
ally exceed those achieved after one year of IFN-based
therapy. However, we think it is important to mention
that the risk of relapse may well be signiﬁcantly higher
after discontinuation of nucleoside analogue than
IFN-based therapy [1]. Higher rates of sustained HBeAg
negativity have been observed in nucleos(t)ide analogue
treated patients who received several months of consol-
idation therapy compared to those who stopped therapy
shortly after HBeAg loss. However, these data are avail-
able for relatively short periods only [1–7], while IFN-in-
duced response has been documented to be durable for
many years [8–13]. Another important observation is
that many HBeAg positive and HBeAg negative patients
with sustained response after (PEG-)IFN therapy even-
tually also cleared serum HBsAg, while HBsAg loss
hardly occurred in nucleos(t)ide analogue treated pa-
tients [8,12,13].q The authors declared that they have a relationship with the
following manufacturers: Roche, Bristol-Myers Squibb, Novartis,
Schering Plough and Gilead.Nucleos(t)ide analogues are easy to use because they
are generally well tolerated and can eﬀectively suppress
HBV replication in virtually all patients. In contrast,
one would like to initiate PEG-IFN only in patients with
a high likelihood of response because of its side eﬀects and
modest response rates. Knowledge of factors associated
with an increased likelihood of response to IFN-based is
therefore essential. Well known predictors of response
to (PEG-)IFN include high baseline ALT and low base-
line HBVDNA, which both seem linearly correlated with
the chance of response [14,15]. Cut-oﬀ levels for ALT and
HBV DNA are therefore diﬃcult to deﬁne. In our opin-
ion, a cut-oﬀ level of 2  ULN instead of 3  ULN for
ALT and of 2  108 IU/ml instead of 2  107 IU/ml for
HBVDNAmight have beenmore appropriate since these
levels are widely used in clinical practice and have been
recommended in several other international guidelines
[16–18]. We disagree that HBV genotype has a poor indi-
vidual predictive value and that genotype alone should
not override choice of treatment. Many previous studies
have shown the importance of HBV genotype for IFN-
based therapy [15,19–24]. Recently, the two largest stud-
ies conducted so far showed thatHBV genotype was actu-
ally the most important predictor of response in both
HBeAgpositive andHBeAgnegative patients, in addition
to ALT and HBV DNA [25,26].
Since sustained oﬀ-treatment response can be
achieved in only a quarter to one-third of PEG-IFN
treated patients, being able to identify non-responders
during the ﬁrst weeks of therapy is important in order
to reduce the number of patients needed to treat. The
authors therefore suggest to determine serum HBV
DNA at week 12 and 24. In case of primary non-re-
sponse, deﬁned as a <1 log10 decline in serum HBV
DNA from baseline after 12 weeks of therapy, they rec-
ommend to discontinue IFN-based therapy. In addition,
they recommended to establish whether virological re-
sponse (deﬁned as an HBV DNA concentration of less
than 2000 IU/ml) has been achieved after 24 weeks of
IFN-based therapy. The consequence of the last ﬁnding
is however not clear. To the best of our knowledge a so-
lid stopping rule for suboptimal responders to IFN-
based therapy has not been identiﬁed so far. In HBV
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genotypes, absence of a 1 log10 decline in HBV DNA at
week 32 accurately predicted non-response [27]. Since
patients with a delayed decline in HBV DNA, i.e. be-
tween weeks 32 and 52 of treatment or after treatment,
still had a considerable chance of 27–31% to clear serum
HBeAg it is diﬃcult to decide on treatment (dis)contin-
uation based on early HBV DNA measurements [27].
Quantitative HBsAg and HBeAg decline during therapy
may more accurately predict (non-)response to PEG-
IFN than HBV DNA levels [28], but many clinicians
do not have access to these quantitative assays.
For HBeAg-positive patients who do not achieve
HBeAg seroconversion during antiviral therapy the
authors state that sustained undetectable HBV DNA is
the next most desirable endpoint. We fully agree that
optimal HBV DNA suppression is desirable in all pa-
tients. Disease progression can be signiﬁcantly dimin-
ished or possibly even prevented if persistent HBV
DNA suppression can be achieved [29]. While undetect-
able HBV DNA is a feasible endpoint for nucleos(t)ide
analogue treated patients who remain HBeAg positive,
undetectable serum HBV DNA can hardly be achieved
in those who remain HBeAg positive after IFN-based
therapy. PEG-IFN induced response was persistent in
the majority of those who underwent HBeAg serocon-
version. Although the proportion of PEG-IFN-treated
patients with undetectable HBV DNA increased with
longer duration of post-treatment follow-up and most
of them were in the inactive carrier state, the majority
of patients still had detectable HBV DNA in the long-
term [8].
Prevention of antiviral resistance is crucial in nucle-
os(t)ide analogue-treated patients. In adefovir-treated
patients detectable serum HBV DNA at week 48 was
strongly associated with a higher risk of antiviral resis-
tance in the long term [30]. Therefore, modiﬁcation of
the treatment regimen is recommended in suboptimal
responders to adefovir therapy. The authors now also rec-
ommend using this strategy in patients receiving entecavir
or tenofovir. One might hypothesize that detectable HBV
DNA after 48 weeks of therapy is associated with an in-
creased risk of antiviral resistance in the long term in these
patients as well. So far, suboptimal responders to enteca-
vir seem however to do well on continued therapy and
tenofovir resistance has not yet been reported. We there-
fore suggest tomodify entecavir or tenofovir therapy only
in case of virological breakthrough in patients who are
fully compliant [31–33].
We conclude that the updated EASL recommenda-
tions provide valuable support for the many physicians
faced with the complex management of patients chron-
ically infected with the hepatitis B virus. Treatment
strategies for chronic hepatitis B have dramatically
improved in the last decade, but many aspects have
not been fully elucidated and controversies persist. Toallow for identiﬁcation of good candidates for PEG-
IFN therapy determination of HBV genotype is impor-
tant in all patients in whom sustained oﬀ-treatment re-
sponse is pursued.
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he need for liver biopsy
main a controversial unresolved issue, at least in our
opinion.
In the recent EASL guidelines, ‘‘a liver biopsy is rec-
ommended for determining the degree of necroinﬂam-
mation and ﬁbrosis in patients with either increased
ALT or HBV DNA levels >2000 IU/ml (or both) since
hepatic morphology can assist the decision to start treat-
ment” and this recommendation is graded as A1 (strong
recommendation based on high quality evidence) [1].
